AU2002223633A1 - Use of stimulators of soluble guanylate cyclase for treating osteoporosis - Google Patents

Use of stimulators of soluble guanylate cyclase for treating osteoporosis

Info

Publication number
AU2002223633A1
AU2002223633A1 AU2002223633A AU2363302A AU2002223633A1 AU 2002223633 A1 AU2002223633 A1 AU 2002223633A1 AU 2002223633 A AU2002223633 A AU 2002223633A AU 2363302 A AU2363302 A AU 2363302A AU 2002223633 A1 AU2002223633 A1 AU 2002223633A1
Authority
AU
Australia
Prior art keywords
stimulators
guanylate cyclase
treating osteoporosis
soluble guanylate
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002223633A
Inventor
Volker Geiss
Erich Sander
Johannes-Peter Stasch
Alexander Straub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU2002223633A1 publication Critical patent/AU2002223633A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
AU2002223633A 2000-11-02 2001-10-22 Use of stimulators of soluble guanylate cyclase for treating osteoporosis Abandoned AU2002223633A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10054278A DE10054278A1 (en) 2000-11-02 2000-11-02 Use of soluble guanylate cyclase stimulators for the treatment of osteoporosis
DE10054278 2000-11-02
PCT/EP2001/012159 WO2002036120A1 (en) 2000-11-02 2001-10-22 Use of stimulators of soluble guanylate cyclase for treating osteoporosis

Publications (1)

Publication Number Publication Date
AU2002223633A1 true AU2002223633A1 (en) 2002-05-15

Family

ID=7661878

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002223633A Abandoned AU2002223633A1 (en) 2000-11-02 2001-10-22 Use of stimulators of soluble guanylate cyclase for treating osteoporosis

Country Status (7)

Country Link
US (1) US20040053915A1 (en)
EP (1) EP1335723A1 (en)
JP (1) JP2004512366A (en)
AU (1) AU2002223633A1 (en)
CA (1) CA2427551A1 (en)
DE (1) DE10054278A1 (en)
WO (1) WO2002036120A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10232572A1 (en) * 2002-07-18 2004-02-05 Bayer Ag New 2,5-disubstituted pyrimidine derivatives
JP2005089457A (en) * 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd Pharmaceutical composition for promoting bone growth or inhibiting bone resorption
DE102007015034A1 (en) * 2007-03-29 2008-10-02 Bayer Healthcare Ag Lactam-substituted dicarboxylic acids and their use
WO2010065275A1 (en) * 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2549875B1 (en) 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
NZ603799A (en) * 2010-05-26 2014-10-31 Bayer Ip Gmbh The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc).
WO2011149921A1 (en) 2010-05-27 2011-12-01 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3291811B1 (en) 2015-05-06 2019-08-07 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
SI3325013T2 (en) 2015-07-23 2023-11-30 Bayer Pharma Aktiengesellschaft Stimulators / activators of soluble guanylat cyclase in combination with a nep-inhibitor and/or an angiotensin aii-antagonist and the use thereof
EP3389655A2 (en) 2015-12-14 2018-10-24 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
US10682210B1 (en) 2016-08-20 2020-06-16 Hybridge, Llc Digital full arch method for immediate definitive dental prostheses
EP3525779A1 (en) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Combination containing sgc stimulators and mineralocorticoid receptor antagonists
CN109890379A (en) 2016-10-11 2019-06-14 拜耳制药股份公司 Combination product comprising sGC activator and mineralocorticoid receptor antagonists
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
SG11202011018PA (en) 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
MX2021000363A (en) 2018-07-11 2021-04-29 Cyclerion Therapeutics Inc USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS.
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19642255A1 (en) * 1996-10-14 1998-04-16 Bayer Ag Use of 1-benzyl-3- (substituted-hetaryl) fused pyrazole derivatives
HUP0001115A3 (en) * 1996-10-14 2001-06-28 Bayer Ag Heterocyclylmethyl-substituted pyrazol derivatives, process for their preparation and pharmaceuticals containing the same
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US6451805B1 (en) * 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834044A1 (en) * 1998-07-29 2000-02-03 Bayer Ag New substituted pyrazole derivatives
DE19834047A1 (en) * 1998-07-29 2000-02-03 Bayer Ag Substituted pyrazole derivatives
AU2900100A (en) * 1999-03-05 2000-09-21 Merck Frosst Canada & Co. Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss

Also Published As

Publication number Publication date
DE10054278A1 (en) 2002-05-08
EP1335723A1 (en) 2003-08-20
WO2002036120A1 (en) 2002-05-10
CA2427551A1 (en) 2003-05-10
JP2004512366A (en) 2004-04-22
US20040053915A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
AU2002223633A1 (en) Use of stimulators of soluble guanylate cyclase for treating osteoporosis
AU2003221536A1 (en) Use of stimulators of soluble guanylate cyclase for treating glaucoma
AU2001231531A1 (en) Follicle stimulating hormones
EP1446114A4 (en) Compositions and methods for treating osteoporosis
GB9824310D0 (en) Activators of soluble guanylate cyclase
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2001289751A1 (en) Selective pde 2 inhibitors, used as medicaments for improving cognition
AU7490900A (en) Chemical compounds and compositions and their use as cathepsin s inhibitors
HRP20040350A2 (en) NOVEL ?-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR US COMPOUNDS
AU2001227966A1 (en) Methods for treating tumors
AUPQ127399A0 (en) Compositions and methods for treating or preventing osteoporosis
IL158693A0 (en) Azole compounds, process for preparation of the same and use thereof
AU2001255602A1 (en) Methods for treating bone tumors
AU6152200A (en) Azolylbenzamides and analogues and their use for treating osteoporosis
AU5160201A (en) Compositions comprising natural agents for treatment of cancer
AU4314199A (en) Compounds, compositions and methods for treating erectile dysfunction
PL358481A1 (en) 6-hydroxy-indazole derivatives for treating glaucoma
HUP0303487A3 (en) Compositions containing 3,7-diazabicyclo [3,3,1] compounds as anthiarhythmic agents and process for preparation of the compounds
AU2001275085A1 (en) Methods, compounds and compositions for treating gout
AU2002322481A1 (en) Use of r-nsaid compounds for anti-hiv treatment
AU5735701A (en) Seed treatment composition
AU2001232263A1 (en) Method of treating seeds
HUP0302430A3 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontience
AU7860800A (en) Adenylate cyclase
AU2002323774A1 (en) New compounds for treating impotence